Explore our Novel Drug Pipeline

Large, durable-remission opportunity in RA (analyst estimates)

With millions affected by Rheumatoid Arthritis worldwide, HLADrvax seeks to address a critical gap in autoimmune care through a novel therapeutic platform focused on disease modification and prevention.

Whats HLADrvax

At Quantum X, we are redefining the future of autoimmune care with HLADrvax—a novel therapeutic solution designed to both treat early-stage Rheumatoid Arthritis (RA) and potentially prevent its onset.

Currently undergoing PHASE 2 Testing, HLADrvax leverages advanced biochemical and biological methodologies to address a critical unmet need in immunosuppressive disease treatment. Our innovative approach targets immune system regulation at its core, offering hope for millions affected by RA.

With HLADrvax, Quantum X is committed to closing the gap in autoimmune therapeutics—driving progress, promoting prevention, and improving lives. HLADrvax has surpassed successful preclinical trials- paving way for successful treatment approaches to deadly disease.

NeuroVax-MS™ is a precision immunotherapy for multiple sclerosis that aims to selectively recalibrate pathogenic immune responses while preserving protective immunity. It is built on a proprietary platform that enables specific modulation of autoreactive pathways implicated in demyelination.

NeuroVax-MS™

OncoVax-p53

We present the design and preclinical validation of OncoVax-p53. Leveraging the nanoparticle delivery expertise of the HLADRvax™ platform. OncoVax-p53 represents a scalable, broadly applicable immunotherapeutic strategy with the potential to benefit millions of cancer patients annually across a wide range of tumor types.